EPO
Hormone that boosts red blood cell production and a prescription anemia medicine; a banned doping substance in endurance sport.

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is EPO?
EPO (erythropoietin) is a hormone made by the kidneys that stimulates the production of red blood cells. The version used as a medicine is made by genetic engineering (for example epoetin), is available on prescription, and is approved for chronic kidney disease, anemia caused by chemotherapy and anemia in premature babies. Endurance athletes, such as cyclists, also use it off-label.
More red blood cells carry more oxygen, but the blood becomes thicker. Anecdotes claim an 8–10% improvement in oxygen uptake, but in blinded, placebo-controlled studies the real performance gain was only about 1–3%. The thickened blood can cause clots, heart attack and stroke, which the regulator's strictest boxed warning also states. In cancer patients it may speed up tumor growth and raise mortality. Rarely, the body makes antibodies against it, causing severe anemia. In competitive sport it is banned in every form.
Mechanism
EPO receptor agonist, erythropoiesis-stimulating
Half-life
5-13 h (subcutaneous)
Onset
7-14 days (reticulocyte rise)
Legal status
USA: FDA Rx (Procrit). EU: Rx. WADA: banned.
No anecdote collected yet.
Data console
Lab data
Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Haug E, Bahr R . Effect of rhEPO administration on serum levels of sTfR and cycling performance.. Med Sci Sports Exerc.
Lamon S, Martin L, Robinson N, Saugy M, Ceaurriz J, Lasne F . Effects of exercise on the isoelectric patterns of erythropoietin.. Clin J Sport Med.
Hayward G, Gaborini L, Robinson N . Mapping of the Pharmacological Effect of Prohibited Substances and Methods to Athletic Physiological Characteristics.. Drug Test Anal.
Haider T, Diaz V, Albert J, Strassburger K, Caicedo A, Reichkendler MH, Lundby C, Gassmann M . A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: The Trial-EPO Study.. Front Physiol.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Rise in hematocrit and blood viscosity with thrombotic events (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction), especially above 50-55% hematocrit or with dehydration – FDA black-box warning.
- Hypertension and blood-pressure spikes; in severe cases hypertensive encephalopathy and seizures.
- Pure red cell aplasia (PRCA) from neutralizing anti-EPO antibodies – rare but serious, causing transfusion-dependent anemia, mainly with subcutaneous dosing.
- Functional iron deficiency: accelerated erythropoiesis depletes iron stores, and without iron supplementation the effect fails and microcytic anemia can develop.
- Flu-like symptoms after injection: joint, muscle and bone pain, chills, headache (especially with intravenous bolus).
- Injection-site reactions: pain, redness, itching and swelling at the subcutaneous injection site.
- In cancer patients, increased tumor progression and mortality with shortened survival (FDA black-box; ESAs can stimulate tumor growth).
- As a doping agent, extreme hematocrit elevation can cause blood "sludging" during the low heart rate of sleep – the phenomenon linked to sudden deaths in the 1990-2000 "EPO era".
Contraindications · 7
- Uncontrolled or severe hypertension – EPO further raises blood pressure and can provoke a hypertensive crisis.
- Thrombophilia or prior thrombotic event (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction) – heightened clotting risk.
- History of EPO-induced pure red cell aplasia (PRCA) or anti-EPO antibodies – all ESA products are contraindicated.
- Elevated baseline hematocrit/polycythemia – further red cell increase causes life-threatening hyperviscosity.
- Active or recent malignancy (with curative treatment intent) – ESAs may increase tumor progression and mortality.
- Untreated iron deficiency or other (B12, folate) deficiency – must be corrected first, otherwise treatment is ineffective.
- Competitive sport: WADA bans all forms (class S2) – its use is doping and is sanctioned independently of the medical risks above.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Effect of rhEPO administration on serum levels of sTfR and cycling performance.
Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Haug E, Bahr R
Effects of exercise on the isoelectric patterns of erythropoietin.
Lamon S, Martin L, Robinson N, Saugy M, Ceaurriz J, Lasne F
Mapping of the Pharmacological Effect of Prohibited Substances and Methods to Athletic Physiological Characteristics.
Hayward G, Gaborini L, Robinson N
A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: The Trial-EPO Study.
Haider T, Diaz V, Albert J, Strassburger K, Caicedo A, Reichkendler MH, Lundby C, Gassmann M
Telegram
Have a question about EPO?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.